Cancer clinical trials in the region Occitanie
174 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
Targeted therapy
Systemic Treatment-Naive
6 main criterias to confirm
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
Systemic Treatment-Naive
None
6 main criterias to confirm
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
Chemotherapy
Radiotherapy
None
7 main criterias to confirm
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
ALK
Systemic Treatment-Naive
Surgery
None
6 main criterias to confirm
Hoffmann-La Roche
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
Systemic Treatment-Naive
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
ALK
EGFR
7 main criterias to confirm
Bristol-Myers Squibb
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
None
6 main criterias to confirm
AstraZeneca
Phase 3
Lung cancer
#NCT06417814
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
EGFR
Targeted therapy
Chemotherapy
Systemic Treatment-Naive
Immunotherapy
Chemotherapy
8 main criterias to confirm
Centre de Cancérologie du Grand Montpellier (Montpellier)
AstraZeneca
Phase 3
Lung cancer
#NCT06472245
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
Other mutation
Immunotherapy
ALK
EGFR
ROS-1
6 main criterias to confirm
Hôpital Larrey (Toulouse )
OSE Immunotherapeutics
Phase 3
Breast cancer
#NCT06195709
HER2 Negative
HR Positive
Metastatic
Targeted therapy
Hormone therapy
1
Chemotherapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
7 main criterias to confirm
Institut du cancer de Montpellier (Montpellier)
Institut Curie
Phase 3
Prostate cancer
#NCT06136624
Adenocarcinoma
Metastatic Castration-resistant
Chemotherapy
Hormone therapy
1
2
3 or more
Systemic Treatment-Naive
6 main criterias to confirm
Institut de cancérologie du Gard (Nîmes)
Merck Sharp & Dohme LLC